HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • Can Charlie Sheen really have doctor-approved unprotected sex?

    Charlie Sheen did more than merely announce he’s HIV-positive on Tuesday morning’s “Today” show — he brought the disease and its myriad treatment methods straight to breakfast tables nationwide. In detailing his HIV journey, Sheen not only relieved himself of blackmail and innuendo — he introduced America to the impressive range of treatment options and procedures now available for the 37 million people living with HIV across the globe. Here’s what it all means for you.

    24 November 2015 | New York Post
  • 'The Fact That I Have HIV Is Not Because Of What I Did - It's Because Of What I Didn't Do'

    UK activist Angelina Namiba talks to Marie Claire about her HIV: "People still ask me ‘how I got’ HIV, almost assuming that I must have done something wrong. But HIV doesn’t discriminate, no matter whether you’re rich or poor, young or old, black or white, you name it. The fact that I have HIV is not because of what I did, it’s because of what I didn’t do. And what I didn’t do is what millions of young people are not doing in this world today – they’re not using a condom."

    19 November 2015 | Marie Claire
  • Sobering Results from Real World HIV Treatment Analysis

    The proportion of people with HIV whose treatment is successful appears lower in the real world than in clinical trials, a researcher said here.

    12 October 2015 | MedPage Today
  • Doctors Find Effective HIV Drug Course Free of Efavirenz

    Once considered part of the gold standard of HIV treatment, alternative regimens can now alleviate concerns about birth defects, psychiatric problems, and even suicide caused by the drug efavirenz. Research published this week shows that three alternative, first-line HIV treatments that do not include efavirenz are just as good at suppressing the virus and are better tolerated.

    08 October 2015 | Healthline
  • Tenofovir Alafenamide Combo Pill Matches Truvada for HIV Efficacy, but Easier on Bones and Kidneys

    A fixed-dose combination pill containing tenofovir alafenamide (TAF) worked as well in a Phase 3 trial as the current Truvada pill containing the older tenofovir disoproxil fumarate (TDF) -- which is used for both HIV treatment and pre-exposure prophylaxis or PrEP -- but causes less kidney and bone toxicity, according to an announcement this week from Gilead Sciences.

    04 September 2015 |
  • The Silent Struggle of HIV Treatment Adherence

    Long-acting antiretroviral medications has the potential to help many people with HIV who face adherence barriers to better health. But that does not mean that it will be a panacea for all adherence issues.

    28 August 2015 | The Body
  • European Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults

    Bristol-Myers Squibb announced today that the European Commission has approved Evotaz (atazanavir 300mg and cobicistat 150mg) tablets in combination with other antiretroviral agents for the treatment of adults with HIV-1 without known mutations associated with resistance to atazanavir.

    20 July 2015 | BMS press release
  • Scripps Research Institute-Designed Drug Candidate Significantly Reduces HIV Reactivation Rate

    HIV-infected patients remain on antiretroviral therapy for life because the virus survives over the long-term in infected dormant cells. Interruption of current types of antiretroviral therapy results in a rebound of the virus and clinical progression to AIDS. But now, scientists from the Florida campus of The Scripps Research Institute (TSRI) have shown that, unlike other antiretroviral therapies, a natural compound called Cortistatin A reduces residual levels of virus from these infected dormant cells, establishing a near-permanent state of latency and greatly diminishing the virus’ capacity for reactivation.

    11 July 2015 | Scripps Research Institute
  • Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide

    Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen that combines Gilead’s emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. The data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naïve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen.

    02 July 2015 | Gilead press release
  • South Korea mulls combining HIV drugs with antivirals to combat MERS

    As the death toll from MERS in South Korea edged to two dozen scientists there say the outbreak is different from in Saudi Arabia and also from its the related virus SARS.

    22 June 2015 | in-Pharma Technologist
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.